Meldex
www.bioprogress.comSymbol: MDX.L
Currently trading at: 11p UP 0.25
Meldex International plc is a specialty pharmaceutical and healthcare business that uses its XGEL polymer technologies to develop and enhance medicines and healthcare products.
It has a portfolio of marketed branded and generic pharmaceutical products and strategic alliances with several global pharmaceutical companies.
The Company is based in Cambridge, Tampa, US and Paris, France.
It is a publicly traded company listed on the Alternative Investment Market of the London Stock Exchange.
It was formerly known as BioProgress plc.
Staff
 , |  Steve Martin BSc (Hons) MRPharmS, Commercial Development DirectorSteve Martin was appointed Director of Pharmaceuticals of Meldex International in November 2005, with broad experience in commercial development and marketing of pharmaceutical and healthcare products. He was appointed to the Board of Meldex International on 25 July 2006. Prior to this appointment he was the founder and Chief Executive Officer of Vienna Healthcare, a business advising on commercial strategy within the global speciality pharmaceutical markets. Previously he founded and ran the Stevenden Healthcare Group; a UK based speciality pharmaceutical company, owned a small chain of community pharmacies and sat on a number of professional and advisory health committees. He has also developed a number of innovative pharmaceutical products including a number of first-to-market generic products and co-founded a specialist clinical research organisation in the area of topical and transdermal medicines. He is a registered and practising pharmacist and began his career with Paydens, a family-run retail pharmacy and distribution company. |
 Jean-Francois Sfarti, President Director General and Chief Executive Officer, Dexo SAJean-Francoise Sfarti is President Director General and Chief Executive Officer of Dexo and has over 30 years of experience in the pharmaceutical industry. He acquired Dexo eight years ago from its founding family and restructured the company to create a virtual operation by outsourcing manufacturing, marketing and distribution. He has developed its product range through the acquisition of pharmaceuticals and by identifying lucrative marketing and product development/extension opportunities. He started his industry career with Sanofi ultimately becoming its Chief Executive in France. He has a degree in Pharmacy (Paris) and in marketing (Issec, Paris). |
Contact details
15 -17 Cambridge Science Park
Milton Road
Cambridge
CB4 0FQ
Tel: +44 (0)1223 394250
Fax: +44 (0)1223 394251
Milton Road
Cambridge
CB4 0FQ
Tel: +44 (0)1223 394250
Fax: +44 (0)1223 394251
